The Southern California Academy of Clinical Oncology
CME Accredited by ACCME/CMA/IMQ

ACO's 113th CANCER SEMINAR
LUNG CANCER 2005: Progress in Treatment
Free Archived Webcast

CME Release Date: Oct 13, 2005. Expiration Date: Oct 12, 2006

ACO is a non-commercial, non-profit professional society of oncologists presenting unbiased, evidence-based, leading-edge CME activities. This free CME seminar will be offered in the form of a live, interactive Webcast video. No special viewing equipment is required – just your Web browser and an Internet connection.

THE PROGRAM

Dr. Ronald B. Natale - Introduction and SCLC Overview
Dr. Gandara - Current Best Therapy for Early and Locally Advanced NSCLC
Dr. Lynch - Innovative Treatment of Advanced/Metastatic NSCLC
Panel and Q&A with Dr. Natale, Dr. Gandara, Dr. Lynch, Dr. Holcombe

 

 
CME ACCREDITATION

The Southern California Academy of Clinical Oncology is accredited by the Institute for Medical Quality and the California Medical Association to provide continuing medical education for physicians.  The Southern California Academy of Clinical Oncology takes responsibility for the content, quality and scientific integrity of this CME activity.

The Southern California Academy of Clinical Oncology designates this educational activity for a maximum of 2.5 hours of Category 1 credit toward the California Medical Association Certification in Continuing Medical Education and the AMA Physician's Recognition Award.  Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

TARGET AUDIENCE

Medical and Radiation Oncologists, Pulmonologists, Thoracic Surgeons, Pathologists, Oncology Nurses, Oncology Pharmacists, Fellows in Training, and Physicians in active clinical practice who are interested and/or involved in the management of patients with lung cancer.

COURSE OBJECTIVES

Needs assessments for this CME activity were derived from documented Southern California epidemiological data, literature reviews and current clinical trials; needs presumed by the Program Committee and expressed needs from ACO members.

At the conclusion of this program, registrants should be able to evaluate:

• recent clinical data regarding targeted therapy and adjuvant chemotherapy in the management of cancer patients
• the role of adjuvant therapy for locally advanced disease
• the current status of neoadjuvant chemotherapy for Stage II/III non-small cell lung cancer
• new therapies and management strategies for metastatic non-small cell lung cancer
• targeted molecular therapies and molecular and genetic assays for patients with lung cancer

EDUCATION GRANTS

This event is supported by Independent Educational Grants from:

THE CALIFORNIA CANCER FOUNDATION
GENENTECH BioONCOLOGY
SANOFI-AVENTIS
LILLY ONCOLOGY

ABOUT ACO

The Academy was established on September 18, 1978 as a Non-Commercial Professional Educational Society. It is a California Nonprofit Public Benefit Corporation for Educational Purposes. IRS Tax Code Section 501(c)(3). Tax I.D. 95-3848332

THE ACO CME PROGRAM COMMITTEE
Alexandra Levine, MD - USC/Norris Cancer Center
Armando Giuliano, MD - John Wayne Cancer Institute
Derek Raghavan, MD, PhD, FACP, FRACP - The Cleveland Clinic
Frank Meyskens, MD - University of California, Irvine
Fred C. Kass, MD - The Santa Barbara Cancer Center
J Randolph Hecht, MD - UCLA
Jonathan S. Berek, MD - UCLA
Robert Morgan, MD - City of Hope
Ronald B. Natale, MD - Cedars Sinai Comprehensive Cancer Center

 
1254 West 6th Street, Suite 318, Los Angeles, CA 90017 (213) 977 1244 | http://www.scaco.org
All online seminar materials copyrighted © 2005, ACO. All Rights Reserved.

ACO does not sell or rent your e-mail address to third parties. You received this e-mail message due to your membership, participation, or interest in ACO. ACO sends various types of e-mail communications. If you do not wish to receive future messages.
click here to unsubscribe